Comorbidities, Concomitant Medications, and Diet as Factors Affecting XXXX Therapy: Results of the CONTROL Surveillance Project.

@entity1 @entity1375 @entity1496 @entity566 @entity1955 @entity1132 @entity354 @entity460 @entity1744 @entity68
BACKGROUND: The CONTROL Surveillance Project was a comprehensive @entity1 -based survey conducted among @entity1375 @entity1 undergoing treatment. The primary objective of the study was to specifically quantify the prevalence of factors adversely affecting @entity1955 therapy. METHODS: @entity1 were selected from a large proprietary database. Those eligible for the study completed a 21-question survey. RESULTS: Of the eligible @entity1375 @entity1 , 925 (92.5  %) were being treated with @entity1955 monotherapy. The mean age was 60.4  years; 755 (81.6  %) were female and 168 (18.2  %) were male. Almost half of those receiving @entity1955 (435, 47.0  %) had at least one comorbid condition that could adversely affect its absorption: @entity354 (33.8  % of @entity1 ), @entity1744 (9.7  %), @entity1132 intolerance (7.8  %), or a history of gastric bypass surgery or bowel resection (3.0  %). Other factors reported by many @entity1 that could adversely affect @entity1955 absorption included use of prescription medications (20.6  %) and over-the-counter medications (34.3  %) used to treat comorbid gastrointestinal (GI) conditions; use of dietary supplements (51.8  %, primarily @entity460 and @entity68 ); and intake of foods/beverages high in fiber, @entity1496 , or soy (68.0  %). Of the 13.4  % who reported difficulty controlling their @entity1375 symptoms, significantly more @entity1 with comorbid GI conditions reported such difficulty (7.8 versus 5.6  %, P  <  0.01). Frequent changes in @entity1955 dosing (two or more dose changes in the past year) were reported by 8.0  % of survey @entity1 . Those with GI comorbidities were nearly twice as likely to have such changes (5.0 versus 3.0  %, P  <  0.01). CONCLUSION: Better initial workup of @entity1 , including identification of relevant GI comorbidities and @entity566 , may help in the early detection of factors that may affect the performance of @entity1955 .
